As of 2022, around 42 percent of all Humira U.S. sales are expected to be at risk due to the drug patent expiring in 2023. This statistic illustrates the share of sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries.
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate Vantage. (May 25, 2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 [Graph]. In Statista. Retrieved December 30, 2024, from https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028." Chart. May 25, 2022. Statista. Accessed December 30, 2024. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. (2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028. Statista. Statista Inc.. Accessed: December 30, 2024. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales Share of Leading Pharmaceutical Products at Risk in The U.S. Due to Approaching Drug Patent Expiries between 2022 and 2028." Statista, Statista Inc., 25 May 2022, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage, Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 Statista, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/ (last visited December 30, 2024)
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 [Graph], Evaluate Vantage, May 25, 2022. [Online]. Available: https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
